A dissolution anomaly involving ticrynafen in simulated intestinal fluid without enzyme.
Data are presented showing that the anomalous dissolution behavior of ticrynafen in simulated intestinal fluid without enzyme is due to the presence of potassium ions in the dissolution medium. Solubility studies indicate that an insoluble 1:1 complex is formed between ticrynafen and its potassium salt. This complex apparently creates an insoluble barrier that prevents complete dissolution of ticrynafen. To determine whether this might also occur in clinical use, a three-way cross-over study in 12 subjects was done. Data from this investigation show that concomitant administration of ticrynafen tablets and potassium in the form of a commercial supplement does not adversely affect bioavailability.